Trials Sponsors Conditions Drugs Pricing

Conditions

Gastric Cancer Peritoneal Metastasis

Outcome Measures

Primary Outcomes (1)

Overall Survival (OS)
Up to 3 years after randomization

Secondary Outcomes (12)

Quality of Life (QoL) assessed by EORTC QLQ-C30 questionnaires
Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
Quality of Life (QoL) assessed by EORTC QLQ-STO22 questionnaires
Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
Pathological Complete Response (pCR) Rate
At the time of radical surgery
R0 Resection Rate
At the time of radical surgery
Complication-Free Survival
Up to 3 years after randomization
+7 more secondary outcomes

Study Arms (2)

Surgery Group

EXPERIMENTAL

Procedure: Radical Gastrectomy with D2 Lymphadenectomy

Standard Treatment Group

ACTIVE COMPARATOR

Drug: Standard Systemic Therapy for Advanced Gastric Cancer

Interventions

Radical Gastrectomy with D2 LymphadenectomyProcedure

Patients undergo curative gastrectomy with D2 lymphadenectomy (laparoscopic, robotic, or open) during second-look laparoscopy after successful conversion therapy. Postoperatively, they receive adjuvant systemic therapy (continuing the preoperative regimen or MDT-modified protocol) for up to 8 cycles total, followed by maintenance therapy for up to 1 year after randomization, or until disease progression, unacceptable toxicity, or withdrawal.

Surgery Group

Standard Systemic Therapy for Advanced Gastric CancerDrug

Eligibility Criteria

Age18 Years - 70 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Patients voluntarily participate in the study, sign the informed consent form, and demonstrate good compliance.
Age ≥ 18 years and ≤ 70 years.

Sponsors & Collaborators

Hua Huang, MD, PhD
Otherlead

Study Sites (31)

Peking University Cancer Hospital

Beijing, Beijing Municipality, 100142, China

NOT_YET_RECRUITING

ziyu liCONTACT+86 010-88121122 ziyu_li@hsc.pku.edu.cn

Chinese PLA General Hospital

Beijing, Beijing Municipality, 100853, China

NOT_YET_RECRUITING

xiaohui duCONTACT+86 010-68182255 duxiaohui301@sina.com

MeSH Terms

Conditions

Stomach Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesStomach Diseases

Central Study Contacts

Hua Huang

CONTACT

+86-13816151816 huahuang@fudan.edu.cn

Study Design

Study Type: interventional
Phase: phase 3
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: SPONSOR INVESTIGATOR
PI Title: Professor, Department of Gastric Surgery, Fudan University Shanghai Cancer Center

Study Record Dates

First Submitted

August 23, 2026

First Posted

August 27, 2026

Study Start

December 1, 2026

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Primary Completion

Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (12)

Study Arms (2)

Surgery Group

Standard Treatment Group

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (31)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (12)

Study Arms (2)

Surgery Group

Standard Treatment Group

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (31)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations